Literature DB >> 26458993

Selection and Application of DNA Aptamer Against Oncogene Amplified in Breast Cancer 1.

Yuan An1, Jie Wu1, Bo Yang2, Zhi Zhu1, Mingxuan Gao1, Chundong Yu3, Chaoyong James Yang4.   

Abstract

Amplified in breast cancer 1 (AIB1), also known as steroid receptor coactivator 3 (SRC-3), is a transcriptional coactivator that interacts with nuclear receptors and other transcription factors to enhance their effects on target gene transcription. AIB1, which acts as a major oncogene, is highly expressed in many human cancers, and has been demonstrated to be a key regulator for tumor initiation, progression, metastasis, invasion, and survival. Recruitment of the transcriptional factor CBP/p300 by CBP/p300-interaction domain (CID) of AIB1 is essential for its transcriptional activation function. In this research, we isolated a DNA aptamer AY-3 that binds to AIB1-CID from a random oligonucleotide library using in vitro screening technology-Systematic Evolution of Ligands by EXponential enrichment (SELEX). The binding affinity of the aptamer to AIB1-CID fusion protein is in the nanomolar range. More importantly, the aptamer was found to disrupt in the interaction between p300 and AIB1. This aptamer has great potential to serve as a therapeutic agent for cancer by inhibiting the coactivation of AIB1.

Entities:  

Keywords:  AIB1; Aptamer; Cancer; SELEX

Mesh:

Substances:

Year:  2015        PMID: 26458993     DOI: 10.1007/s00239-015-9703-y

Source DB:  PubMed          Journal:  J Mol Evol        ISSN: 0022-2844            Impact factor:   2.395


  35 in total

1.  Nucleic Acid Selection and the Challenge of Combinatorial Chemistry.

Authors:  Scott E. Osborne; Andrew D. Ellington
Journal:  Chem Rev       Date:  1997-04-01       Impact factor: 60.622

Review 2.  Aptamers: prospects in therapeutics and biomedicine.

Authors:  Amy C Yan; Kathryn M Bell; Megan M Breeden; Andrew D Ellington
Journal:  Front Biosci       Date:  2005-05-01

3.  In vitro selection of structure-switching signaling aptamers.

Authors:  Razvan Nutiu; Yingfu Li
Journal:  Angew Chem Int Ed Engl       Date:  2005-02-04       Impact factor: 15.336

4.  The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways.

Authors:  J J Voegel; M J Heine; M Tini; V Vivat; P Chambon; H Gronemeyer
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

5.  Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection.

Authors:  X Y Guan; P S Meltzer; W S Dalton; J M Trent
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

6.  ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion.

Authors:  Weiwen Long; Charles E Foulds; Jun Qin; Jian Liu; Chen Ding; David M Lonard; Luisa M Solis; Ignacio I Wistuba; Jun Qin; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  J Clin Invest       Date:  2012-04-16       Impact factor: 14.808

7.  SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration.

Authors:  Weiwen Long; Ping Yi; Larbi Amazit; Heather L LaMarca; Felicity Ashcroft; Rakesh Kumar; Michael A Mancini; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  Mol Cell       Date:  2010-02-12       Impact factor: 17.970

8.  The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.

Authors:  Sridharan Soundararajan; Weiwei Chen; Eleanor K Spicer; Nigel Courtenay-Luck; Daniel J Fernandes
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

Review 9.  Steroid receptor coactivator-3 as a potential molecular target for cancer therapy.

Authors:  Jean Ching-Yi Tien; Jianming Xu
Journal:  Expert Opin Ther Targets       Date:  2012-08-27       Impact factor: 6.902

10.  ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance.

Authors:  Maggie C Louie; June X Zou; Alina Rabinovich; Hong-Wu Chen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

View more
  3 in total

1.  A Quarter Century of In Vitro Selection.

Authors:  Yingfu Li
Journal:  J Mol Evol       Date:  2015-11-24       Impact factor: 2.395

Review 2.  Ligand-targeted theranostic nanomedicines against cancer.

Authors:  Virginia J Yao; Sara D'Angelo; Kimberly S Butler; Christophe Theron; Tracey L Smith; Serena Marchiò; Juri G Gelovani; Richard L Sidman; Andrey S Dobroff; C Jeffrey Brinker; Andrew R M Bradbury; Wadih Arap; Renata Pasqualini
Journal:  J Control Release       Date:  2016-01-06       Impact factor: 9.776

Review 3.  SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.

Authors:  Licen Li; Chu-Xia Deng; Qiang Chen
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.